PhotoMedex (PHMD) Earning Somewhat Favorable Media Coverage, Report Shows

News coverage about PhotoMedex (NASDAQ:PHMD) has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. PhotoMedex earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 45.2353255579025 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

COPYRIGHT VIOLATION WARNING: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.com-unik.info/2017/11/01/photomedex-phmd-earning-somewhat-favorable-media-coverage-report-shows.html.

About PhotoMedex

PhotoMedex, Inc is a global health products and services company providing integrated disease management and solutions to dermatologists, professional aestheticians and consumers. The Company provides products and services that address skin diseases and conditions, including acne and photo damage. The Company operates through three business segments: Consumer segment, Physician Recurring segment and Professional segment.

Insider Buying and Selling by Quarter for PhotoMedex (NASDAQ:PHMD)

What are top analysts saying about PhotoMedex Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PhotoMedex Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit